Concord Biotech Limited vs Piramal Pharma Limited
Last updated: 25 October 2026
Concord Biotech vs Piramal Pharma: A MoneyDock Comparison
In the dynamic Indian pharmaceutical landscape, two companies often draw investor attention for different reasons: Concord Biotech Limited and Piramal Pharma Limited. Both operate within the broad healthcare sector, with Concord Biotech specializing in the development and manufacturing of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients) and Piramal Pharma boasting a diverse portfolio spanning Contract Development and Manufacturing Organization (CDMO) services, Complex Hospital Generics (CHG), and India Consumer Healthcare. This comparison aims to dissect their recent market performance and key metrics to help investors understand their current standing, using only the provided financial data.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Piramal Pharma Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹191.07 |
| 52W High | ₹1579.40 | ₹226.62 |
| 52W Low | ₹1014.80 | ₹133.27 |
| 1-Year Return | -7.65% | 13.80% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: Without the Trailing P/E and Market Cap data, a direct valuation comparison based on these metrics is not possible. However, looking at the current prices, Concord Biotech trades at a significantly higher price point of ₹1229.30 compared to Piramal Pharma's ₹191.07. This alone doesn't indicate which is 'cheaper' without context on earnings or total market capitalization, which are unavailable here.
Returns: On the returns front, Piramal Pharma Limited clearly outperforms Concord Biotech. Piramal Pharma has delivered a positive 1-Year Return of 13.80%, indicating healthy growth over the past year. In contrast, Concord Biotech Limited has seen a negative 1-Year Return of -7.65%, suggesting a period of underperformance for its shareholders. For investors prioritizing recent performance, Piramal Pharma holds a distinct advantage.
Stability/Volatility (based on 52-Week Range): Examining the 52-week ranges provides some insight into price volatility. Concord Biotech's current price of ₹1229.30 is closer to its 52-week low of ₹1014.80 than its 52-week high of ₹1579.40, indicating it has fallen considerably from its peak. Its range of ₹564.60 (₹1579.40 - ₹1014.80) is substantial given its current price. Piramal Pharma's current price of ₹191.07 is also closer to its 52-week high of ₹226.62 than its 52-week low of ₹133.27. Its range of ₹93.35 (₹226.62 - ₹133.27) is proportionally smaller compared to its current price, suggesting relatively less volatility compared to Concord Biotech within their respective price scales. Piramal Pharma appears to be trading stronger within its yearly range.
MoneyDock Verdict
MoneyDock Verdict
Given the available data, here's how different investor profiles might view these two pharma stocks:
For Aggressive Investors: Piramal Pharma Limited might be more appealing due to its positive 1-Year Return (13.80%) and current price being closer to its 52-week high, indicating recent momentum. While specific growth catalysts aren't detailed, the recent performance suggests a more upward trajectory.
For Conservative Investors: Neither company presents a clear 'conservative' winner based solely on this limited data, especially with N/A for P/E and Market Cap. However, Concord Biotech's negative 1-Year Return (-7.65%) might make it a riskier proposition for those seeking stability and capital preservation in the short term. Piramal Pharma's positive return might offer more comfort, but without deeper fundamental analysis, caution is advised for both.
For Long-Term SIP Investors: Without P/E ratios and market capitalization, it's challenging to assess long-term value. However, a long-term SIP investor might look for companies that demonstrate consistent growth and reasonable valuations. Piramal Pharma's positive 1-Year Return could be a sign of underlying strength, while Concord Biotech would require a deeper dive to understand the reasons for its negative return and potential for future recovery. A long-term investor would need to consider future growth prospects, market position, and management quality, which are not covered by these metrics.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.